舒芬太尼与丁丙诺啡在术后自控镇痛中的疗效与安全性评价  

Sulfentanyl versus buprenorphine for controlled intravenous analgesia on patients undergoing maxillofacial operation

作　　者：闫俊杰[1] 刘伟东[1] 江银华[1] 陈慧敏[2] 

机构地区：[1]丽水市人民医院口腔科,浙江丽水323000 [2]浙江省中医院保健科,杭州310006

出　　处：《中国临床药理学杂志》2015年第3期193-195,共3页The Chinese Journal of Clinical Pharmacology

基　　金：浙江中医药科技计划基金资助项目(2009GA002)

摘　　要：目的评价舒芬太尼(SF)对比丁丙诺啡(BP)在口腔颌面部手术(OMS)后自控镇静脉痛(PCIA)的临床疗效及安全性。方法 79例OMS患者随机分为舒芬太尼组(41例)和丁丙诺非组(38例),舒芬太尼组术后予以舒芬太尼50μg;丁丙诺非组术后给予丁丙诺非0.6 mg,分别于术后2,8,24,48 h用视觉模拟评份量表和镇静评分量表对患者术后疼痛及镇静情况进行评定,同时记录2组患者术后48 h内生命体征及不良反应。结果舒芬太尼组与丁丙诺非组患者镇痛、镇静评分及生命体征指标差异均无统计学意义(P>0.05),但舒芬太尼组患者药物相关不良反应发生率显著低于丁丙诺非组(P<0.05)。结论舒芬太尼与丁丙诺非用于OMS术后自控镇痛、镇静效果无差异,但舒芬太尼药品不良反应低于丁丙诺非。Objective To assess the clinical efficacy and safety of sulfentanyl versus buprenorphine for controlled intravenous analgesia on patients undergoing oral and maxillofacial surgery（ OMS）,as the patient controlled intravenous analgesia（ PCIA） way. Methods A total of 79 patients who received OMS were randomly divided into sulfentanyl group（ n = 41） and buprenorphine group（ n = 38）. Patients in sulfentanyl group were given sulfentanyl 50 μg and patients in BP group were given buprenorphine 0. 6 mg. Visual analogue scale（ VAS） and sedation scale were used to evaluate the pain control and sedation effects at the time points of 2,8,24 and 48 hours after operation. The vital signs and adverse events of the patients in two groups were recorded in 48 hours after operation. Results No difference was found between the two groups in the aspects of pain control,sedation effects and vital signs（ P〉0. 05）. Adverse drug reactions were much more in buprenorphine group than those in sulfentanyl group（ P〈0. 05）. Conclusion There were no differences in pain control and sedation effects between sulfentanyl and buprenorphine for controlled intravenous analgesia on patients undergoing OMS,but the total adverse drug reactions induced by buprenorphine were more than those induced by sulfentanyl.

关 键 词：舒芬太尼 丁丙诺啡 术后自控镇痛 颌面部手术 临床疗效 

分 类 号：R614.2[医药卫生—麻醉学] R971[医药卫生—外科学]